Loading
CASI Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Sept 2022.
CASI Pharmaceuticals, Inc.: what insiders have been doing
CASI Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of CASI Pharmaceuticals, Inc. in twelve months, the latest record being from 8 September 2022.
Looking back to 2016, when coverage begins, insiders filed 21 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
21
Thresholds
n/a
Buy Volume
€1M
21 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -49.2%Entry 4.29 · Close at T+365 2.18
- -80.1%Entry 9.40 · Close at T+365 1.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Revenue33.9M
Gross profit15.7M46% margin
Net income-36.6M-107.8% margin
Last declaration on 8 September 2022
Declarations21 total
19,162 shares@ US$3.893210.2% of flowCommon StockSEC:0000899243-22-030690:0
Canonical exit: 5 Dec 2022 (T+90)
24,975 shares@ US$3.74512.6% of flowCommon StockSEC:0000899243-22-030336:0
Canonical exit: 29 Nov 2022 (T+90)
5,000 shares@ US$3.75022.5% of flowCommon StockSEC:0000899243-22-029897:0
Canonical exit: 22 Nov 2022 (T+90)
171,116 shares@ US$3.269474.7% of flowCommon StockSEC:0000899243-22-029564:0
Canonical exit: 17 Nov 2022 (T+90)
972,708 sharesCommon StockSEC:0000950103-16-010539:0
Canonical exit: 5 Jun 2013 (T+90)
68,958 sharesCommon StockSEC:0000950103-16-010539:1
Canonical exit: 5 Jun 2013 (T+90)
400 sharesCommon StockSEC:0001144204-16-076472:0
Canonical exit: 18 Apr 2016 (T+90)
400 sharesCommon StockSEC:0001144204-16-076472:1
Canonical exit: 18 Apr 2016 (T+90)
4,163 sharesCommon StockSEC:0001144204-16-076472:2
Canonical exit: 18 Apr 2016 (T+90)
11,837 sharesCommon StockSEC:0001144204-16-076472:3
Canonical exit: 18 Apr 2016 (T+90)
7,537 sharesCommon StockSEC:0001144204-16-076485:0
Canonical exit: 18 Apr 2016 (T+90)
1,100 sharesCommon StockSEC:0001144204-16-076485:1
Canonical exit: 18 Apr 2016 (T+90)
6,063 sharesCommon StockSEC:0001144204-16-076485:2
Canonical exit: 18 Apr 2016 (T+90)
300 sharesCommon StockSEC:0001144204-16-076485:3
Canonical exit: 18 Apr 2016 (T+90)
21 of 21 declarations
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on NASDAQ, with its ordinary shares later beginning to trade on the OTCQB market under the ticker CASIF after Nasdaq delisting proceedings announced in February 2026. The company is headquartered in South San Francisco, California, while also maintaining offices in Beijing, China, plus manufacturing and R&D capabilities in Wuxi. That footprint reflects a long-standing cross-border operating model spanning the United States and Greater China. CASI was incorporated in 1991, giving it a long corporate history even though its strategy has evolved materially over time.
Today, the company is best understood as a clinical-stage biotech focused on CID-103, an investigational anti-CD38 monoclonal antibody being developed for organ transplant rejection and autoimmune diseases. This is a meaningful strategic pivot from CASI’s earlier emphasis on the development and commercialization of hematology and oncology products. Historically, the company built a China-oriented commercialization platform and has been associated with specialty products such as EVOMELA, a melphalan formulation for injection, alongside other oncology and hematology assets. Its earlier model combined product licensing, regulatory execution, and local commercialization capabilities in China, which differentiated it from many U.S. micro- and small-cap biotechs.
Read moreShow less
From a competitive standpoint, CASI occupies a niche position rather than competing as a broad-based pharmaceutical company. Its investment case is centered on a small number of assets, especially CID-103, where the company is pursuing a differentiated mechanism in areas of high unmet medical need. CASI’s messaging emphasizes that antibody-mediated rejection remains a major problem in kidney transplantation and that there is currently no FDA-approved treatment for AMR, underscoring the potential clinical and commercial significance if development succeeds. That said, the company remains highly dependent on execution, funding, and clinical outcomes.
Recent corporate developments have been material. In February 2026, CASI said it had received a Nasdaq Hearings Panel determination to delist the company’s securities, with trading suspension beginning February 26, 2026. In April 2026, the company disclosed that its shares had started trading on the OTCQB under CASIF. Earlier 2025 updates also highlighted ongoing development work and efforts to extend runway for clinical programs. For investors, especially those in France, Belgium, and Switzerland, CASI should be viewed as a high-risk, event-driven biotech story with an international operating presence, a U.S. base, and a concentrated pipeline exposure to a single lead program.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
